Evgen Pharma PLC Posting of Annual Report and Notice of AGM (3049C)
June 18 2021 - 1:00AM
UK Regulatory
TIDMEVG
RNS Number : 3049C
Evgen Pharma PLC
18 June 2021
Evgen Pharma plc
("Evgen" or the "Company")
Posting of Annual Report and Notice of AGM
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company, announces that its Annual Report and Accounts for the year
ended 31 March 2021, the Notice of Annual General Meeting ("AGM")
and a Form of Proxy will be posted to shareholders later today and
will be available to download from the Company website shortly.
The Company will hold its AGM on Tuesday, 13 July 2021 at 2pm at
its offices in Alderley Park.
Since laws and the UK Government's guidance regarding the
COVID-19 pandemic current on Tuesday 13 July 2021 continue to
include the enforcement of social distancing and restrictions on
indoor meetings, shareholders will not be permitted to attend the
AGM and a closed meeting will be held. Accordingly, the business at
the AGM will be curtailed to the formal business section only, with
no wider presentations on business performance or question and
answer session and any relevant shareholder updates will be made
via RNS announcements.
Similarly, proxies other than the Chairman will not be able to
attend the Meeting in person or cast the shareholder's vote.
Shareholders are therefore strongly encouraged to appoint the
Chairman of the AGM as their proxy. Details on how to do this are
set out on the Form of Proxy being posted to shareholders
today.
Any shareholder wishing to ask questions regarding the business
of the AGM is encouraged to submit their questions to the Board by
email to evgen@walbrookpr.com at least seven days in advance of the
AGM. The Board will consider all questions and, if appropriate,
will provide a written response.
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Dr Huw Jones, CEO
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7876 741 001 / +44 (0)7980 541
Anna Dunphy / Paul McManus 893
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The has its headquarters at Alderley Park, Cheshire , and its
registered office is at the Liverpool Science Park, Liverpool. It
is listed on the AIM market of the London Stock Exchange and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAGPUQAQUPGGAM
(END) Dow Jones Newswires
June 18, 2021 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2023 to Apr 2024